Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia

Urology

Volumn 67, Issue 2, 2006, Pages 225-231

  Kaplan, Steven A ^a   Neutel, Joel ^b  

^a Herbert Irving Pavilion ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; CHLORTALIDONE; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; LISINOPRIL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRAZOSIN; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; VARDENAFIL;

AGING; ASTHENIA; CLINICAL TRIAL; COMORBIDITY; DIZZINESS; DRUG ACTIVITY; DRUG SAFETY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; HYPOTENSION; LONG TERM CARE; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOMATOLOGY; SYNCOPE; TACHYCARDIA; TREATMENT OUTCOME; URINARY TRACT DISEASE; VASODILATATION; VENOUS STASIS; VERTIGO;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADRENERGIC ALPHA-ANTAGONISTS; AGE FACTORS; AGED; HUMANS; HYPERTENSION; MALE; PROSTATIC HYPERPLASIA; VASODILATION;

EID: 31944432410     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.09.020     Document Type: Review

References (46)

1. C.G. Roehrborn, J.D. McConnell Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia P.C. Walsh A.B. Retik E.D. Vaughan Campbell's Urology 2002 WB Saunders Philadelphia 1297 1336
2. R. Rosen, J. Altwein, P. Boyle Lower urinary tract symptoms and male sexual dysfunction the Multinational Survey of the Aging Male (MSAM-7) Eur Urol 44 2003 637 649
3. A. Tubaro, M. Polito, L. Giambroni Sexual function in patients with LUTS suggestive of BPH Eur Urol 40 suppl 1 2001 19 22
4. R.C. Rosen Prevalence and risk factors of sexual dysfunction in men and women Curr Psychiatry Rep 2 2000 189 195
5. R. Sadovsky Integrating erectile dysfunction treatment into primary care practice Am J Med 109 suppl 9A 2000 22S 28S
6. Package insert: Levitra® (vardenafil HCl) tablets [2003 revision]. Last update: 2003. Available at: http://www.univgraph.com/bayer/inserts/levitra. pdf. Accessed September 12, 2003.
7. Cialis® (tadalafil) tablets: package insert. Last update: 2004. Available at: http://pi.lilly.com/us/cialis-pi.pdf. Accessed May 11, 2004.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 283 2000 1967 1975
9. E.D. Vaughan Jr Medical management of benign prostatic hyperplasia - are two drugs better than one? N Engl J Med 349 2003 2449 2451
10. J.D. McConnell, C.G. Roehrborn, O.M. Bautista The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398
11. M. Caine, A. Pfau, S. Perlberg The use of alpha-adrenergic blockers in benign prostatic obstruction Br J Urol 48 1976 255 263
12. A. Jardin, K-E. Andersson, C. Chapple α1-Adrenoceptor antagonists in the treatment of BPH C. Chatelain G.E. Demas K.T. Foo Benign Prostatic Hyperplasia 2001 Health Publication Plymouth, United Kingdom 461 477
13. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction Eur Urol 36 1999 1 13
14. B. Akduman, E.D. Crawford Terazosin, doxazosin, and prazosin current clinical experience Urology 58 suppl 6A 2001 49 54
15. C. Forray, S.A. Noble Subtype selective α1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia Expert Opin Invest Drugs 8 1999 2073 2094
16. N. Mottet, F. Bressolle, V. Delmas Prostatic tissue distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration Eur Urol 44 2003 101 105
17. K. McKeage, G.L. Plosker Alfuzosin a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia Drugs 62 2002 633 653
18. C.G. Roehrborn ALFUS Study Group Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia a randomized, placebo-controlled trial Urology 58 2001 953 959
19. H. Lepor Tamsulosin Investigator Group Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia Urology 51 1998 892 900
20. P. Narayan, A. Tewari Members of the United States 93-01 Study Group A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia J Urol 160 1998 1701 1706
21. A. Fawzy, K. Braun, G.P. Lewis Multicenter Study Group Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients a multicenter study J Urol 154 1995 105 109
22. H. Lepor, S. Auerbach, A. Puras-Baez A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia J Urol 148 1992 1467 1474
23. Package insert: Uroxatral® (alfuzosin HCl extended-release tablets). Last update: 2003. Available at: http://www.sanofi-synthelabous.com/products/ pi_uroxatral/pi_uroxatral.html. Accessed October 31, 2003.
24. Flomax® (tamsulosin hydrochloride) capsules prescribing information Physicians' Desk Reference 2004 Thomson PDR Montvale, NJ 1006 1009
25. B.R. Davis, J.A. Cutler, D.J. Gordon ALLHAT Research Group Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Am J Hypertens 9 1996 342 360
26. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med 157 1997 2413 2446
27. Guidelines Subcommittee of the World Health Organization-International Society of Hypertension (WHO-ISH) Mild Hypertension Liaison Committee 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension J Hypertens 17 1999 151 183
28. F.H. Messerli Implications of discontinuation of doxazosin arm of ALLHAT Lancet 355 2000 863 864
29. L. Lasagna Diuretics vs α-blockers for treatment of hypertension lessons from ALLHAT JAMA 283 2000 2013 2014
30. C.G. Roehrborn, P. van Kerrebroeck, J. Nordling Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia a pooled analysis of three double-blind, placebo-controlled studies BJU Int 92 2003 257 261
31. M.C. Michel, H.-U. Bressel, M. Goepel A 6-month large-scale study into the safety of tamsulosin Br J Clin Pharmacol 51 2001 609 614
32. J.B. Meigs, B. Mohr, M.J. Barry Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men J Clin Epidemiol 54 2001 935 944
33. E.Q. Wang, H.L. Fung Prazosin potentiates the acute hypotensive effects of nitroglycerin but does not attenuate nitrate tolerance in normal conscious rats J Cardiovasc Pharmacol 43 2004 341 346
34. R.C. Rosen, K.E. McKenna PDE-5 inhibition and sexual response pharmacological mechanisms and clinical outcomes Annu Rev Sex Res 13 2002 36 88
35. I. Goldstein, T.F. Lue, H. Padma-Nathan Sildenafil Study Group Oral sildenafil in the treatment of erectile dysfunction N Engl J Med 338 1998 1397 1404
36. W.J. Hellstrom, M. Gittelman, G. Karlin Vardenafil Study Group Vardenafil for treatment of men with erectile dysfunction efficacy and safety in a randomized, double-blind, placebo-controlled trial J Androl 23 2002 763 771
37. G.B. Brock, C.G. McMahon, K.K. Chen Efficacy and safety of tadalafil for the treatment of erectile dysfunction results of integrated analyses J Urol 168 2002 1332 1336
38. L.S. Marks, C. Duda, F.J. Dorey Treatment of erectile dysfunction with sildenafil Urology 53 1999 19 24
39. J.P. Jarow, A.L. Burnett, A.M. Geringer Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment J Urol 162 1999 722 725
40. D.P. Mikhailidis, M.A. Khan, H.J. Milionis The treatment of hypertension in patients with erectile dysfunction Curr Med Res Opin 16 suppl 1 2000 s31 s36
41. R.A. Kloner, S.H. Mullin, T. Shook Erectile dysfunction in the cardiac patient how common and should we treat? J Urol 170 2003 S46 S50
42. A.D. Seftel Erectile dysfunction in the elderly epidemiology, etiology and approaches to treatment J Urol 169 2003 1999 2007
43. U. Thadani, W. Smith, S. Nash The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease J Am Coll Cardiol 40 2002 2006 2012
44. D. Tran, L.G. Howes Cardiovascular safety of sildenafil Drug Saf 26 2003 453 460
45. Package insert: Viagra® (sildenafil citrate) tablets [2003 revision]. Last update: 2003. Available at: www.pfizer.com/download/uspi_viagra.pdf. Accessed September 12, 2003.
46. A.F. De Rose, M. Giglio, P. Traverso Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy Int J Impot Res 14 2002 50 53